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RTable 1Men (n[320) Women (n[230) p-valueAge (years) 69.9 [62.25-78.0] 73.33 [66.0-80.25] 0.35Race (%) <0.001White 70.3 46.4Black 7.2 23.0Hispanic 19.7 26.3Asian 0.6 1.4Other 2.2 2.9Body mass index (kg/m2) 28.2 [25.0-27.4] 28.4 [27.4-30.5] 0.89Medical history (%)Diabetes mellitus 51.6 53.3 0.64Hypertension 83.7 89.0 0.004Hyperlipidemia 80.0 84.3 0.16Coronary artery disease 64.0 50.0 0.002Prior peripheral artery revascularization 24.1 24.3 1.00Tobacco use 27.4 11.8 <0.001Medication use (%)Aspirin 57.5 49.5 0.60Clopidogrel 51.9 45.7 0.84Cilostazol 11.6 5.7 0.06Statin 63.4 53.8 0.43Insulin 17.8 12.9 0.81Laboratory dataWhite blood cell count (x 103 cells/mL) 7.7 [6.2-8.9] 10.3 [6.0-9.1] 0.99Neutrophil/lymphocyte ratio 2.86 [1.65-3.50] 1.97 [1.65-3.53] 0.70Platelet count (x 103 cells/uL) 214 [170-250] 259 [192-309] <0.001Creatinine (mg/dL) 1.38 [0.90-1.30] 1.17 [0.71-1.60] <0.001LDL-cholesterol (mg/dL) 86 [62-104] 92 [64-116] 0.14HDL-cholesterol (mg/dL) 46 [36-53] 55 [44-78] <0.001Triglycerides (mg/dL) 149 [92-187] 130 [81-200] 0.015Glucose (mg/dL) 132 [90-149] 129 [89-149] 0.99Resting ankle-brachial index (ABI)Right 0.75 [0.69-0.98] 0.67 [0.41-0.97] 0.10Left 0.79 [0.65-1.03] 0.56 [0.59-0.99] 0.07Critical limb ischemia with ABI <0.4 (%) 42.8 42.4 0.93Continuous data are presented as median [interquartile range]
Table 2Men (n[320) Women (n[230) p-valueExtent of disease (%) 0.74Mild or moderate disease 12.5 10.5Isolated severe suprapopliteal disease 31.3 32.4Isolated severe infrapopliteal disease 15.6 13.3Severe multilevel disease 40.6 43.8Men (n¼243) Women (n¼168)
Type of procedural intervention (%)Stent placement 59.3 54.8 0.42Use of adjunctive device therapy
(e.g. atherectomy, re-entry device)33.3 36.9 0.46Target vessel revascularization (%) 11.9 16.3 0.16CRT-308
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BACKGROUND The JetStream Navitus (JS) atherectomy device is a rotational cutter
with aspiration capability designed to treat infrainguinal arterial obstructive disease.
JS XC can be operated with blades down (BD) (2.1 or 2.4 mm perimeter) or blades up
(BU) (3.0 or 3.4 mm perimeter) to treat femoropopliteal obstructive disease. It is
unclear whether an orbital effect is present while operating the JS leading to a largerminimal luminal area (MLA) than predicted based on device size. Also, the minimum
MLA and plaque surface area (PSA) needed in a typical size femoral artery (5-6 mm)
for the device to be effective has not been deﬁned. Using an in-stent restenosis (ISR)
porcine model and intravascular ultrasound (IVUS) assessment of lesions these
questions were addressed.
METHOD 4 pigs (8 limbs) were implanted with overlapping SMART (Cordis) nitinol
self-expanding stents using an overstretch balloon/stent model. ISR was treated 1
month after stent implantation with an initial 2 blades down (BD) runs followed by
4 BU runs. IVUS measurements were performed at baseline, after 2 BD runs, and
after each BU run on a total of 24 lesions. Minimal luminal area (MLA, mm2) and
plaque surface area (PSA, %) were obtained. 1-sample Wilcoxon signed-rank test
was performed between MLA obtained after BU runs and theoretical maximal MLA
of the XC 2.4-3.4 cutter with BU. MLA and PSA at baseline were plotted against net
MLA and PSA gain (BU - baseline) respectively. The minimum MLA and PSA at
baseline needed for a positive increase in MLA and reduction in PSA were
determined.
RESULTS The femoral artery mean diameter was 4.7 mm. A strong correlation was
present between MLA at baseline and after BU runs (Pearson correlation p¼0.006) and
between PSA at baseline and after BU runs (p<0.0001). An approximateMLA9.0mm2
or PSA  60% were needed to see a positive effect of atherectomy on treated lesion
(i.e. increase in MLA or reduction in PSA). Theoretical MLA achievable from the XC
BU 2.4-3.4 device is 9.08 mm2 (A ¼ pr2 using r¼3.4/2¼1.7mm). No difference is
seen between this calculated MLA and the IVUS measured MLAs after BU
runs using 1-sample Wilcoxon test indicating no orbital effect of the device on tissue
cutting.
CONCLUSION JS XC 2.4-3.4 BU achieved positive cutting of ISR tissue inside a 4.7 mm
femoral artery when the baseline lesion MLA was  9.0 mm2 or PSA  60% on IVUS.
No orbital cutting was seen with the JS BU as MLA obtained after treatment was not
different from theoretical MLA.CRT-309
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BACKGROUND Recently, it was reported that statins are associated with lower rates
of major adverse cardiovascular events and amputations in critical limb ischemia
(CLI) patients (pts). However, the impact of statin administration duration on clinical
outcomes for pts undergoing percutaneous transluminal angioplasty (PTA) due to
peripheral arterial disease (PAD) is uncertain.
METHODS A total 286 pts underwent PTA for PAD from Oct 2004 to Feb 2013 from
prospective PTA registry was enrolled. Major adverse cardiovascular and extremity
events (MACEEs) were deﬁned as the composite end-point consisted of cardiac death,
myocardial infarction, repeat PTA, and amputation. The incidence of MACEEs ac-
cording to statin duration up to 1-year was evaluated.
RESULTS The incidences of total MACEEs was in 33.2% (95/286 pts); cardiac death 7
(2.4%), myocardial infarction 3 (1.0%), major and minor amputation 56 (19.6%), repeat
PTA 46 (16.1%). Not only the univariate logistic regression analysis, but also in
multivariate logistic regression adjusted by age, gender, hypertension, diabetes, ce-
rebrovascular accident, and chronic renal failure, there was signiﬁcant risk reduction
for MACEES in statin use duration 180 and 360 days group, not in statin use duration
30 and 90 days (Table).
CONCLUSIONS In our study, prolonged statin duration at least longer than 6 months
was associated with reduced risk of MACEES compared with shorter statin duration in
pts undergoing PTA for PAD.












RTable. Association with statin use duration and MACEEs
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BACKGROUND The JetStream Navitus (JS) atherectomy device (Boston Scientiﬁc) is a
rotational cutter with aspiration capability to treat infrainguinal arterial obstructive
disease. Intravascular ultrasound (IVUS) assessment of the number of blades up (BU)
runs needed to achieve optimal tissue debulking in in-stent restenosis (ISR) using the
JS is unknown.
METHOD 4 pigs (8 limbs) were implanted with overlapping SMART (Cordis)
nitinol self-expanding stents using an overstretch balloon/stent model. In-stent
restenosis (ISR) was treated 1 month after stent implantation with an initial 2
blades down (BD) runs followed by 4 BU runs. A run was deﬁned as a single proximal
to distal pass of the device within the stent at a speed of approximately 1-2 mm
per sec. IVUS quantitative measurements were performed at baseline, after 2 BD runs,
and after each BU run (BU1, BU2, BU3, BU4) on a total of 24 lesions. Minimal
luminal area (MLA, mm2) and plaque surface area (PSA, %) were obtained in
each of the proximal, mid, and distal segments of the lesion. Wilcoxon signed-rank
test and paired t-test (1-tail) were performed to compare baseline, BD and BU 1 to
4 runs.
RESULTS The mean baseline MLA was 7.8  2.7 mm2. Following 2BD and 1 BU
runs the mean MLAs were 8.1  2.5 mm2 (p<0.044) and 8.7  2.0 mm2 (p¼0.007)
when compared to baseline MLA respectively. There was also a signiﬁcant increase
in MLA between 2BD runs and BU1 run (p¼0.033) and between BU1 and BU2 runs
(9.4  2.4, p¼0.007). No statistical difference in MLA was seen between BU 2 to 3
runs (P>0.05). Similarly, PSA was signiﬁcantly reduced between baseline (65.2  11.7)
and 2 BD (63.0  10.5, p¼0.015) and BU1 (60.7  9.2, p¼0.011) runs, and between
BU1 and BU2 runs (57.5  7.5, p¼0.025). No differences in PSA was seen between
the BU2, BU3 and BU4 runs (p¼0.12). Vessel area at site of treatment remained
unchanged between baseline and BU4 run (23.3  5.8 vs. 22.5  4.9 mm2 respectively,
p¼0.73) indicating that the increase in MLA and reduction in PSA is a true plaque
cutting rather than a dottering effect by the JS. There were no IVUS stent strut
disruption following JS treatment which was later conﬁrmed by high resolution
radiographs.
CONCLUSION JS achieved optimal and true tissue debulking after 2 BD and 2 BU runs.
Based on these IVUS observations, performing more than 2 BU runs in a femoral artery
ISR model is unlikely to yield further tissue debulking.CRT-311
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BACKGROUND The JetStream Navitus (JS) (Boston Scientiﬁc) is an atherectomy de-
vice that uses rotational cutting and aspiration to treat infringuinal arterial obstruc-
tive disease. The number of blades up (BU) runs needed to achieve safe and maximum
tissue debulking using the JS is unknown.
METHOD In this swine model, 4 animals (8 limbs) were implanted with overlapping
SMART (Cordis) nitinol self-expanding stents 1 month prior to JS treatment. In-stent
restenosis (ISR) was treated with an initial 2 blades down (BD) runs followed by 4 BU
runs. A run was deﬁned as a single proximal to distal pass of the device within the
stent at a speed of approximately 1-2 mm per sec. Quantitative vascular angiography
using edge detection technique (QVA) was performed at baseline, after 2 BD runs, and
after each BU run (BU1, BU2, BU3, BU4). Minimal luminal diameter (MLD), plaque
surface area (PSA) and percent stenosis (PS) within the treated stented segment (n¼8)
were measured by QVA. Descriptive analysis was performed on all angiographic
variables. Wilcoxon signed-rank test and paired t-test (1-tail) were performed to
compare baseline, BD and BU 1 to 4 runs.RESULTS The mean baseline (n¼8) MLD was 1.73  0.84 mm. Following 2BD and 1 BU
runs the mean MLDs were 2.56  0.7 mm (p¼0.025) and 3.12  0.39 mm (p¼0.005)
when compared to baseline MLD respectively. There was also a signiﬁcant increase in
MLD between 2BD runs and BU1 run (p¼0.005). No statistical difference in MLD was
seen between BU runs (P > 0.05). Similarly, PSA was signiﬁcantly reduced between
baseline (83.9  14.8) and 2 BD (67.7  17.0, p¼0.005) and BU1 (55.4  9.0, p¼0.005)
runs and between BU1 and BU2 runs (50.7  9.7, p < 0.05). No differences in PSA was
seen between the BU2, BU3 and BU4 runs (p>0.05). Finally, PS was reduced from a
mean of 63.13  16.91 to 44.97  15.08 (p¼0.005) with BD runs and to 33.51  6.73
(p¼0.005) with BU1 run. There was also a signiﬁcant reduction in PS between 2 BD
runs and BU1 run (p¼0.01) and between BU1 and BU2 runs (30.1  7.0, p¼0.05). No
difference between PS was seen between BU 2 to 4 runs (p¼0.10). There were no
angiographic complications or stent strut discontinuities on high resolution radio-
graphs following JS treatment.
CONCLUSION JS achieved optimal tissue debulking after 2 BU runs with no further
gain in debulking after the second BU run. Based on these observations, operators
treating ISR with the JS device may need to limit their debulking to 2 BD and 2 BU
runs performed at 1 to 2 mm per second speed to achieve optimal debulking and
minimize the chance of complications from additional BU runs.CRT-312
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BACKGROUND The Jetstream NAVITUS System (JS) (Boston Scientiﬁc) is a rotating
and aspirating atherectomy catheter approved for active removal of atherosclerotic
disease and thrombus in infrainguinal arteries. The post market JET registry is a
multicenter, prospective study that is currently evaluating femoropopliteal artery
(FP) patency at 1 year, acute procedural success and major adverse events (MAE) in
denovo and non-stent restenotic lesions following treatment with the JS device. We
present preliminary acute procedural success and in-hospital outcomes from
currently enrolled patients in JET.
METHOD The JET has a target enrollment of 500 patients with Rutherford category
1-3 denovo or non stent restenotic FP lesions, > 4 cm in length and > 70% in
severity. Lesions with in-stent restenosis, or crossed via a subintimal approach or
treated within 1 month prior to index procedure are excluded. There were no
prespeciﬁed criteria for stenting post JS which was left to operator’s discretion.
Procedural success is deﬁned as  30% residual diameter stenosis following athe-
rectomy  adjunctive therapy. In-hospital major adverse events (MAE) included
amputation, death, and distal embolization (DE) requiring separate intervention or
hospitalization. Calcium was graded from 0 to 4 by the operator (0¼none, 1¼ < 25% of
treated segment length (TSL), 2¼ 25-50% of TSL, 3¼>50% of TSL and 4¼dense cal-
cium of entire TSL).
RESULTS Preliminary results from the ﬁrst 155 patients enrolled in the JET registry
are as follows: mean age 66  11 yrs., males 68.0%, diabetics 42%, smoking history
51.0%, hypertension 80.0%, de novo lesions 90.0%, lesion length 220  290 mm,
reference diameter 6.0  4 mm, pretreatment stenosis 91  10%, post JS residual
stenosis 47  21% and post JS þ adjunctive treatment 9  8%. Adjunctive stenting was
33.0%. Distal embolic protection was used in 19% of patients. Distal embolization
requiring treatment was 2%. There were no other in-hospital device-related compli-
cations reported. Calcium scoring (0 to 4 respectively) were as follows: Preprocedure:
7, 15, 25, 31 and 22%; post procedure: 15, 28, 26, 22 and 8%
CONCLUSION Preliminary data from the JET registry shows a high procedural success
and low rate of acute complications in treating denovo and non-stent restenotic le-
sions with low rate of DE despite a relatively low use of embolic ﬁlter protection and a
trend toward improvement in calcium grade.RENAL INTERVENTION
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BACKGROUND The safety and precision of PCI performed with the CorPath robotic
system been demonstrated. Percutaneous treatment of ostial renal artery stenosis
requires precise stent positioning. We examined the feasibility of robot assisted renal
artery stent implantation.
